BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has reached a new agreement with Medigene AG (“Medigene”) in relation to

NTD Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will offer testing for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020 through its sister company Viracor Eurofins.

Thermo Fisher Scientific, the world leader in serving science, today announced that its Thermo Scientific Cascadion SM Clinical Analyzer is now commercially available in the U.S. with the Cascadion SM 25-Hydroxy Vitamin D assay. Designed to deliver accurate, traceable measurements of vitamin D2 (ergocalciferol) and D3 (cholecalciferol), this serum assay reports total vitamin D results alongside its components.

CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their advancement to Phase III Clinical Trial for PF-06939926.

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., Chief Medical Officer will present at the Barclays Global Healthcare Conference on Wednesday, March 11 th at 4:50 p.m. ET.

Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced today the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $7.89 per share, before underwriting discounts and commissions.

Matt Maxwell, CEO of Accel Clinical Services, announced that Clinical Research Investments has officially become Accel Clinical Services (ACS), effective immediately. Maxwell explained the new name

Mylan N.V. announced that the U.S. District Court of New Jersey found the device patent claims asserted by Sanofi against Mylan’s insulin glargine product not infringed and invalid for lack of written description.

According to the data of qichacha.com, the number of enterprises involved in the medical devices business grew dramatically from January 1 to February 10, 2020.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clin